期刊文献+

去铁胺对β-地中海贫血儿童听力的影响 被引量:2

下载PDF
导出
摘要 目的探讨去铁胺对β-地中海贫血儿童听力的影响。方法28例地中海贫血患儿,去铁胺每天30mg/kg,使用便携式皮下输液泵,每周使用2~6次。所有患儿于进行纯音测定并检测血红蛋白浓度和铁蛋白浓度。结果28例患儿中7例(25%)出现不同程度的听力丧失,频率在4000~8000Hz,其中轻度听力丧失3例,中度听力丧失2例,重度听力丧失2例。听力丧失与听力正常组之间的年龄、血红蛋白浓度、铁蛋白浓度、每次和每周去铁胺剂量均无显著统计学差异。结论地中海贫血儿童低剂量和不规则使用去铁胺也可能出现听力损害,对使用去铁胺的患儿应定期进行听力检测以避免出现不可逆听力损害。
出处 《南方医科大学学报》 CAS CSCD 北大核心 2008年第8期1489-1489,1491,共2页 Journal of Southern Medical University
基金 深圳市科技局基金(200602086)
  • 相关文献

参考文献6

  • 1Kontzoglou G, Koussi A, Tsatra J, et al. Sensorineural hearing loss in children with thalassemia major in Northern Greece[J]. Int J Pediatr Otorhinolaryngol, 1996, 35 (3): 223-30.
  • 2Chen SH, Liang DC, Lin HC, et al. Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients [ J ]. J Pediatr Hematol Oncol, 2005, 27(12): 651-3.
  • 3Styles LA, Vichinsky EP. Ototoxicity in hemoglobinopathy patients chelated with desferrioxamine [J]. J Pediatr Hematol Oncol, 1996, 18(1): 42-5.
  • 4Karimi M, Asadi Pooya AA, Khademi B, et al. Evaluation of the incidence of sensorineural heating loss in beta-thalassemia major patients under regular chelation therapy with desferrioxamine [J]. Acta Haematol, 2002, 108( 2): 79-83.
  • 5Kontzoglou G, Koussi A, Economou M, et al. Long term audiological evaluation of beta-thalassemic patients [J]. Acta Otorhinolaryngol Belg, 2004, 58(2): 113-7.
  • 6Ambrosetti U, Donde E, Piatti G, et al. Audiological evaluation in adult beta-thalassemia major patients under regular chelation treatment[J]. Pharmacol Res, 2000, 42(5): 485-7.

同被引文献31

  • 1林琳,孙建和,黄德亮,朱光明,侯宁.胎儿耳蜗血管纹的扫描电镜观察[J].临床耳鼻咽喉科杂志,2005,19(4):157-159. 被引量:8
  • 2路虹,杨逸,徐鸥,张迪,韩海霞,于丽萍.顺铂对耳蜗螺旋神经节细胞毒性作用及机制[J].中国耳鼻咽喉头颈外科,2004,11(6):355-357. 被引量:7
  • 3王丽萍,王苹,杜波,杜宝东.缺氧对体外培养大鼠耳蜗毛细胞的损伤作用[J].吉林大学学报(医学版),2007,33(2):276-278. 被引量:6
  • 4Piga A,Gaglioti C,Fogliaeco E,et al.Comparative effects of deferiprone and deferoxmnine on survival and cardiac disease in patients with thalassaemia major:a retrospective analysis[J].Haematologica,2003,88(5):489-496.
  • 5De Sanctis V,Pinamonti A,Di Palma A,et al.Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine[J].Eur J Pediatr,1996,155(5):368-372.
  • 6Triantafyllou N,Fisfis M,Sideris G,et al.Neurophysio-logical and neuro-otological study of homozygous beta-thalassemia under long-term desferrioxamine (DFO)[J].Acta Neurol Scand,1991,83(5):306-308.
  • 7Karimi M,Asadi Pooya AA,Khademi B,et al.Evalu-ation of the incidence of sensorineural hearing loss in beta-thalassemia major patients under regular chelation therapy with desferrioxamine[J].Acta Haematol,2002,108(2):79-83.
  • 8Chen SH,Liang DC,Lin HC,et al.Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients[J].J Pediatr Hematol Oncol,2005,27(12):651-653.
  • 9Kontzoglou G,Koussi A,Tsatra J,et al.Sensorineural hearing loss in children with thalassemia major in Northern Greece[J].Int J Pediatr Otorhinolaryngol,1996,35(3):223-230.
  • 10De Virgiliis S. Argiolu F. Sanna G. et al. Audiotory involve?ment in thalassemia major[J]. Acta Haematol.1979.61 :213.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部